SMART Apps
We have also developed four SMART-on-FHIR apps for natural product drug interactions of importance. These apps are available at https://napdi-cds.org/?page_id=25. A small description of each app is listed below.
- NPDI-CDS for Cannabidiol – Direct Oral Anticoagulants (DOACs): This SMART app focuses on supporting clinician decision making for situations where a patient is at risk for an adverse event due to DOAC toxicity caused by inhibition of the metabolism of DOAC by an inhibitor of P-glycoprotein(P-gp).
- NPDI-CDS for Cannabidiol – Clopidogrel: This SMART app focuses on supporting clinician decision making for situations where a patient is at risk for an adverse event due to reduced clopidogrel efficacy caused by inhibition of the metabolism of clopidogrel to an active drug by an inhibitor of cytochrome P450 2C19.
- NPDI-CDS for Cannabidiol – Warfarin: This SMART app focuses on supporting clinician decision making for situations where a patient is at risk for an adverse event due to warfarin toxicity caused by inhibition of the metabolism of warfarin by an inhibitor of cytochrome P450 2C9.
- NPDI-CDS for Kratom – Oxycodone: This SMART app focuses on supporting clinician decision making for situations where a patient is at risk for an adverse event due to oxycodone toxicity caused by inhibition of the metabolism of oxycodone by an inhibitor of cytochrome P450 2D6.
Publications
2022
Chapin MR, Kane-Gill SL, Li X, Abanyie K, Taneja SB, Egbert S, Paine MF, Boyce RD. Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports. Pharmacol Res Perspect. 2025 Feb;13(1):e70046. doi: 10.1002/prp2.70046. PMID: 39719830; PMCID: PMC11668912.
Chapin MR, Kane-Gill SL, Li X, Abanyie K, Taneja SB, Egbert S, Paine MF, Boyce RD. Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System. Pharmacol Res Perspect. 2025 Feb;13(1):e70047. doi: 10.1002/prp2.70047. PMID: 39719832; PMCID: PMC11668913.